Early prophylactic anticoagulation after subarachnoid hemorrhage decreases systemic ischemia and improves outcome.


Journal

Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039

Informations de publication

Date de publication:
08 2021
Historique:
received: 19 11 2020
revised: 23 06 2021
accepted: 07 07 2021
pubmed: 19 7 2021
medline: 22 1 2022
entrez: 18 7 2021
Statut: ppublish

Résumé

In neurosurgical perioperative treatment, especially in connection with subarachnoid hemorrhage (SAH), the prophylactic anticoagulation (AC) regimen is still considered controversial. The goal of this retrospective study was to assess how the time point of low-molecular-weight heparin (LMWH) initiation (ToH) affects ischemic and hemorrhagic events after SAH. 370 patients who received acute treatment for non-traumatic SAH between 2011 and 2018 were included, and 208 patients were followed up after 12 months. We assessed how the ToH affects ischemic and hemorrhagic events as well as outcome scores. Statistical analysis was performed using the Mann-Whitney U-Test, the chi-squared test, Fisher's exact test, and univariate binomial logistic regression. P-values below 0.05 were considered statistically significant. The incidence of systemic ischemia was 4.6%, cerebral ischemia 33.5%, and intracranial rebleeding 14.6%. Delaying ToH (measured in hours) increases systemic ischemia (p = 0.009). The odds ratio for the impact of delayed anticoagulation on systemic ischemia is 1.013 per hour (95%CI of OR 1.001-1.024). ToH has no influence on cerebral ischemia or intracranial rebleeding. Early anticoagulation was associated with a more favorable Glasgow Outcome Score 12 months after discharge (ToH within 48 h: p = 0.006). ToH did not affect mortality or readmission rates. Initiating prophylactic AC with LMWH later than 48 h after aneurysm repair or admission impairs outcomes 12 months after discharge. It might be safe for patients with non-traumatic SAH to be anticoagulated with prophylactic doses of heparin within 24 h after admission or the treatment of source of bleeding (SoB). Early AC with prophylactic LMWH does not promote rebleeding.

Sections du résumé

BACKGROUND
In neurosurgical perioperative treatment, especially in connection with subarachnoid hemorrhage (SAH), the prophylactic anticoagulation (AC) regimen is still considered controversial. The goal of this retrospective study was to assess how the time point of low-molecular-weight heparin (LMWH) initiation (ToH) affects ischemic and hemorrhagic events after SAH.
METHODS
370 patients who received acute treatment for non-traumatic SAH between 2011 and 2018 were included, and 208 patients were followed up after 12 months. We assessed how the ToH affects ischemic and hemorrhagic events as well as outcome scores. Statistical analysis was performed using the Mann-Whitney U-Test, the chi-squared test, Fisher's exact test, and univariate binomial logistic regression. P-values below 0.05 were considered statistically significant.
RESULTS
The incidence of systemic ischemia was 4.6%, cerebral ischemia 33.5%, and intracranial rebleeding 14.6%. Delaying ToH (measured in hours) increases systemic ischemia (p = 0.009). The odds ratio for the impact of delayed anticoagulation on systemic ischemia is 1.013 per hour (95%CI of OR 1.001-1.024). ToH has no influence on cerebral ischemia or intracranial rebleeding. Early anticoagulation was associated with a more favorable Glasgow Outcome Score 12 months after discharge (ToH within 48 h: p = 0.006). ToH did not affect mortality or readmission rates.
CONCLUSIONS
Initiating prophylactic AC with LMWH later than 48 h after aneurysm repair or admission impairs outcomes 12 months after discharge. It might be safe for patients with non-traumatic SAH to be anticoagulated with prophylactic doses of heparin within 24 h after admission or the treatment of source of bleeding (SoB). Early AC with prophylactic LMWH does not promote rebleeding.

Identifiants

pubmed: 34274657
pii: S0303-8467(21)00338-3
doi: 10.1016/j.clineuro.2021.106809
pii:
doi:

Substances chimiques

Anticoagulants 0
Heparin, Low-Molecular-Weight 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106809

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Annika Hantsche (A)

University Hospital Leipzig, Department of Neurosurgery, Liebigstrasse 20, 04103 Leipzig, Germany.

Florian Wilhelmy (F)

University Hospital Leipzig, Department of Neurosurgery, Liebigstrasse 20, 04103 Leipzig, Germany. Electronic address: florian.wilhelmy@medizin.uni-leipzig.de.

Johannes Kasper (J)

University Hospital Leipzig, Department of Neurosurgery, Liebigstrasse 20, 04103 Leipzig, Germany.

Tim Wende (T)

University Hospital Leipzig, Department of Neurosurgery, Liebigstrasse 20, 04103 Leipzig, Germany.

Gordian Hamerla (G)

University Hospital Leipzig, Division of Neuroradiology, Liebigstrasse 20, 04103 Leipzig, Germany.

Stefan Rasche (S)

University Hospital Leipzig, Department of Anesthesiology and Intensive Care, Liebigstrasse 20, 04103 Leipzig, Germany.

Jürgen Meixensberger (J)

University Hospital Leipzig, Department of Neurosurgery, Liebigstrasse 20, 04103 Leipzig, Germany.

Dirk Lindner (D)

University Hospital Leipzig, Department of Neurosurgery, Liebigstrasse 20, 04103 Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH